KAIST reprograms colon cancer cells to normal
- On February 5, 2025, KAIST said Kwang-Hyun Cho’s team identified a molecular switch that pushed colon cancer cells toward a normal-like state. - In a March 2025 Advanced Science paper, the team named MYB, HDAC2 and FOXA2 as master regulators whose simultaneous inhibition drove reversion. - The work was reported in Advanced Science and KAIST said follow-on studies will test cancer-reversion approaches in additional tumor types.
South Korea’s KAIST has spent the past two years publishing a pair of linked colorectal-cancer studies that aim to do something most cancer treatments do not: push malignant cells back toward a normal state instead of killing them outright. In December 2024 and February 2025, the institute said a team led by bio and brain engineering professor Kwang-Hyun Cho showed that colon cancer cells could be shifted into “normal-like” states in laboratory and animal experiments. The work underpins social-media claims this week that KAIST “reprogrammed” colon cancer cells to normal, but the published studies are narrower than that shorthand suggests. The experiments were done in cell lines, organoid models and animal studies, not in human patients. ### What exactly did the KAIST team report? A March 2025 paper in *Advanced Science* said Cho’s group built a computational framework called BENEIN to analyze single-cell transcriptome data from human large-intestinal tissue and identify “master regulators” of normal differentiation. The paper said MYB, HDAC2 and FOXA2 emerged as the key regulators and that simultaneous knockdown of those regulators could revert colorectal cancer cells into “normal-like enterocytes” in vitro and in vivo. (engineering.kaist.ac.kr) A February 5, 2025 KAIST release described a second framework, REVERT, aimed at the “critical transition” when normal cells become cancer cells. KAIST said the team applied that approach to colon cancer cells and confirmed in molecular-cell experiments that the cells could recover characteristics of normal cells. ### Did the researchers say the cancer cells became fully normal? (advanced.onlinelibrary.wiley.com) The KAIST and *Advanced Science* materials repeatedly use the phrase “normal-like,” not fully normal. The December 24, 2024 KAIST engineering release said the cells were converted into “a state resembling normal colon cells,” and the paper said the intervention reverted colorectal cancer cells into “normal-like enterocytes.” (news.kaist.ac.kr) The same sources said the evidence came from transcriptome comparisons, morphology and malignancy-related assays. KAIST said the treated cells showed recovery of normal-cell characteristics, while the paper described a combination of induced differentiation and suppressed malignancy. ### How was this different from standard cancer treatment? (engineering.kaist.ac.kr) KAIST said the approach was designed as a “cancer reversal” strategy rather than a cell-killing one. The December 2024 release said current therapies generally aim to eliminate cancer cells, while Cho’s team sought to convert them into a state resembling normal cells “without killing them.” (engineering.kaist.ac.kr) Cho said in the February 2025 release that the team had found “a molecular switch” that could revert cancer-cell fate by capturing the transition point before cells become irreversibly cancerous. That description is KAIST’s characterization of the work; the studies do not report a clinical therapy or patient outcomes. ### What evidence was actually shown? The December 2024 KAIST release said the first study’s findings were confirmed through molecular and cellular experiments as well as animal studies. (engineering.kaist.ac.kr) The February 2025 release said the follow-up work used single-cell RNA sequencing data and systems-biology analysis of matched colon cancer and normal-colon organoids to identify a reversion switch, then tested the result in colon cancer cells. (news.kaist.ac.kr) The March 2025 *Advanced Science* paper said the simultaneous knockdown of MYB, HDAC2 and FOXA2 was the effective combination. The paper presents that as a systems-level intervention on differentiation pathways, not a ready-to-use drug. ### So what should readers not overstate? The published record does not show a cure for colon cancer in people. (engineering.kaist.ac.kr) The sources available from KAIST and *Advanced Science* describe preclinical work in colorectal cancer models and say the method may be applied to other cancers in future research. KAIST said the next step is broader development of “reversion therapies” for other cancers, and the two *Advanced Science* papers provide the named frameworks — BENEIN and REVERT — that other researchers can examine and test. (advanced.onlinelibrary.wiley.com) (engineering.kaist.ac.kr)
